Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuzheng Xiaoliu Decoction is a traditional Chinese medicine (TCM) multi-herbal formulation used primarily as an adjunct therapy in cancer treatment. It is composed of several herbs commonly including Atractylodes macrocephala (Baizhu), Astragalus mongholicus (Huangqi), Smilax glabra (Fuling), Scleromitrion diffusum (Bai Hua She She Cao), Curcuma aromatica (Ezhu), Codonopsis pilosula (Dangshen), and Glycyrrhiza glabra (Gancao)[4][7]. The formula aims to "strengthen healthy qi" and eliminate pathogenic factors according to TCM theory. Modern pharmacological studies suggest it may exert anti-tumor effects by modulating immune function, reducing tumor markers, improving quality of life in cancer patients, and potentially acting on multiple molecular targets such as the Akt-mTOR pathway[2][7]. It has been studied for use in hepatocellular carcinoma and other cancers as an adjunct to chemotherapy or supportive care[2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fuzheng xiaoliu decoction.